<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ethosuximide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00593</strong>&#160; (APRD00318)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00593/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00593/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00593.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00593.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00593.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00593.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00593.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00593">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(&#177;)-2-ethyl-2-methylsuccinimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-ethyl-2-methylsuccinimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>3-ethyl-3-methyl-2,5-pyrrolidinedione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Atysmal</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Ethosuximid</td><td>German</td><td>INN</td></tr><tr><td>Ethosuximidum</td><td>Latin</td><td>INN</td></tr><tr><td>Etosuximida</td><td>Spanish</td><td>INN</td></tr><tr><td>Thilopemal</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>&#947;-ethyl-&#947;-methyl-succinimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Emeside</td><td>Chemidex</td></tr><tr><td>Ethymal</td><td>Apotex Europe</td></tr><tr><td>Etoxin</td><td>Apsen</td></tr><tr><td>Petimid</td><td>Osel</td></tr><tr><td>Petinimid</td><td>Gerot</td></tr><tr><td>Petnidan</td><td>Desitin</td></tr><tr><td>Suxilep</td><td>Jenapharm</td></tr><tr><td>Suxinutin</td><td>McNeil</td></tr><tr><td>Zarondan</td><td>Pfizer</td></tr><tr><td>Zarontin</td><td>Pfizer</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/succinimides">Succinimides</a></li></ul></td></tr><tr><th>CAS number</th><td>77-67-8</td></tr><tr><th>Weight</th><td>Average: 141.1677<br>Monoisotopic: 141.078978601</td></tr><tr><th>Chemical Formula</th><td>C<sub>7</sub>H<sub>11</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>HAPOVYFOVVWLRS-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-ethyl-3-methylpyrrolidine-2,5-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC1(C)CC(=O)NC1=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00593.gif?1265922771">show</a>(8.34 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyrrolidines</td></tr><tr><th>Subclass</th><td>Pyrrolidones</td></tr><tr><th>Direct parent</th><td>Pyrrolidones</td></tr><tr><th>Alternative parents</th><td>N-unsubstituted Carboxylic Acid Imides; Secondary Carboxylic Acid Amides; Lactams; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>carboxylic acid imide, n-unsubstituted; carboxylic acid imide; secondary carboxylic acid amide; carboxamide group; lactam; carboxylic acid derivative; carboxylic acid; polyamine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrrolidones. These are compounds containing a pyrrolidine ring which bears a ketone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of petit mal epilepsy.</td></tr><tr><th>Pharmacodynamics</th><td>Used in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.</td></tr><tr><th>Mechanism of action</th><td>Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.</td></tr><tr><th>Absorption</th><td>Bioavailability following oral administration is 93%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, via CYP3A4 and CYP2E1.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>53 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9983</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5262</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5832</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7859</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9923</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8492</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5108</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9242</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9072</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9276</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.93</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.858
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8526
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9299
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9213 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9939
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9795
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Banner pharmacaps inc</li>
<li>Convenant pharma inc</li>
<li>Parke davis div warner lambert co</li>
<li>Mikart inc</li>
<li>Pharmaceutical assoc inc div beach products</li>
<li>Teva pharmaceuticals usa</li>
<li>Parke davis pharmaceutical research div warner lambert co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Barr Pharmaceuticals</li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Association</li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.swisscaps.com">Swiss Caps Ag</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.versapharm.com">Versapharm Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Syrup</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Ethosuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>